Palatin Technologies
Developed bremelanotide (Vyleesi), sold it to Cosette, and now works on next-generation MC4R peptides for obesity.
Share price
$8.60
What analysts expect
Buy
Buy100%
Hold0%
Sell0%
Price target for the next 12 months
$55.00Up 818% compared with the current price
Price now $5.99Average targetLowest $50.00 to highest $60.00
2 analysts. Only two analysts cover it, and both targets are months old. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $13M
- Yearly profit
- Loss $6.3M
- Company value
- $16M
Revenue and profit for the last twelve months reported.
Peptides in this book
- BremelanotidePrescription
Recent news
- 2026-10-01 Palatin reports full-year fiscal 2026 results and business update PR Newswire
Risk in the news: An AlphaStreet analysis flagged liquidity risk alongside fiscal 2026 revenue growth.
Prices are delayed and figures rounded. Not investment advice.